CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$3.35
-0.09 (-2.76%)
âŧ
5d:
+4.36%
30d:
+0.9%
90d:
+17.13%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -14.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -14.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.15
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$4.44
24.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $3.35, which is considered slightly high relative to its 30-day fair value range of $3.21 to $3.37. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.1) compared to its historical average (20.6). Remarkably, the market is currently pricing in an annual earnings decline of 14.1% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $3.15, while resistance sits at $3.46.
Market Sentiment: CRON scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $3.01. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $3.15, while resistance sits at $3.46.
Market Sentiment: CRON scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $3.01. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.21 -
$3.37
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
33.3%
Protect Your Profits
Holding CRON? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 10.1% above Wall St target ($3.01)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.21 -
$3.37
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.16
Resistance Level
$3.47
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.06
Wall Street Target
$3.01
(-10.1%)
Revenue Growth (YoY)
58.4%
Earnings Growth (YoY)
126.8%
Profit Margin
39.1%
Valuation Discount vs History
-14.1% cheaper
PE vs Historical
13.1 vs 20.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.1%
(market-implied from PE analysis)
1-Year Target
$3.02
(-10%)
2-Year Target
$2.71
(-19%)
3-Year Target
$2.44
(-27%)
3-Yr Target (if PE normalizes)
(PE: 13â21)
$3.85
(+15%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.5%)
$6.50
(+94%)
Base:
(SPY PE: 13.1, Growth: 8.5%)
$4.27
(+28%)
Bear:
(PE: 11.1, Growth: 8.5%)
$3.63
(+8%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 18.13 | Current EPS (TTM): $0.19
Bull Case
$5.12
(+53%)
Analyst growth 35.1%, PE expands to 19.9
Base Case
$4.65
(+39%)
Market implied 35.1%, PE stable at 18.1
Bear Case
$2.34
(-30%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.1 to 20.6
Stabilization Target:
$5.29
(+57.8%)
PE Expansion Potential:
+57.8%
Share & Embed Analysis
Last updated: October 23, 2026 10:54 PM ET
Data refreshes hourly during market hours. Next update: 11:54 PM
Data refreshes hourly during market hours. Next update: 11:54 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
